Small molecule therapeutic - Collaboration Pharmaceuticals
Latest Information Update: 29 Mar 2023
At a glance
- Originator Collaborations Pharmaceuticals
- Class Small molecules; Vascular disorder therapies
- Mechanism of Action CCR3 receptor antagonists; CCR4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Stroke
Most Recent Events
- 21 Mar 2023 Small molecule therapeutic - Collaboration Pharmaceuticals is available for licensing as of 21 Mar 2023. https://www.collaborationspharma.com/pipeline
- 21 Mar 2023 Preclinical trials in Stroke in USA (unspecified route), before March 2023 (Collaboration pharmaceuticals pipeline, March 2023)